Navigation Links
Heidelberg cardiac surgeons implant world's first new DeBakey Heart Assist Device
Date:8/17/2009

At the end of July 2009, a team of cardiac surgeons headed by Professor Dr. Matthias Karck, Director of the Department of Cardiac Surgery at Heidelberg University Hospital, was the first in the world to implant the HeartAssist 5 ventricular assist device, the modern version of the DeBakey VAD. The device augments the pumping function of the left ventricle in an especially effective, gentle and quiet manner. The pump weighs 92 grams and is made of titanium and plastic. It pumps blood from the weakened or failed left ventricle into the aorta.

"Following the 3.5 hour surgery, the patient is doing fine," reports Professor Karck. The 50-year-old woman suffered from heart failure that could not be effectively treated with medication. Since a heart transplant was not an option due to medical reasons, the implanted heart pump will now assist her heart permanently.

Bridging the waiting time for a heart transplant

"The heart pump can also be used as a bridge-to-transplant while the patient waits for a matching donor heart," says Dr. Arjang Ruhparwar, senior registrar in the Department of Cardiac Surgery in Heidelberg. When a donor heart becomes available, the pump and the diseased heart are both removed and replaced by the new donor heart.

The DeBakey VAD was first developed in the 1990s in cooperation with NASA by Professor Michael DeBakey, the renowned American cardiac surgeon at the Baylor College of Medicine in Houston, who died in 2008 at the age of 99. The modern version of the device, the HeartAssist 5, is manufactured by US company MicroMed Cardiovascular. It is considered to be a fifth generation VAD because it can be implanted adjacent to the heart and has an exclusive flow probe that provides direct, accurate measurement of blood flow from the left ventricle to the aorta. The new miniature device is light, easy-to-handle and can be monitored and controlled externally.

Patients can live a normal life at home

"The new device has great advantages at only 92 g, it is the smallest and lightest approved VAD in Europe that can completely replace the function of the left ventricle and it works very quietly and effectively with a high flow coefficient," explains Professor Karck. Thus, patients are able to live a nearly normal life at home.

In Europe, the HeartAssist 5 has CE Marks for both adult and pediatric use. In the U.S., the HeartAssist 5, formerly DeBakey VAD Child, is the only FDA-approved pediatric VAD. A bridge-to-transplant IDE clinical study is currently underway in the U.S. for adults.


'/>"/>

Contact: Dr. Matthias Karck
Matthias.karck@med.uni-heidelberg.de
062-215-66272
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
2. Cardiac Science Reports Q2 Revenue; Resumes AED Shipments
3. Electronic Health Records Help Cardiac Patients Remain Healthy
4. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
5. Harrison City ROCKS! Set for August 15, Music Festival to Benefit Cardiac Research at Childrens Hospital of Pittsburgh
6. Patriot Scientific Corporation Announces Cardiac Science Corporations Purchase of a Moore Microprocessor Patent(TM) Portfolio License
7. Many Heart Attack Patients Not Referred to Cardiac Rehab
8. Worlds First Cardiac Adult Stem Cell Patient and Physicians Discuss Clinical Trial
9. Roche Cardiac 200 Offers Rapid Cardiac Diagnostics for the Point of Care
10. Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths
11. Cardiac CT is more cost effective when managing low-risk patients with chest pain
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Heidelberg cardiac surgeons implant world's first new DeBakey Heart Assist Device
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... FLINT, Mich. , Oct. 2, 2017 ... acquired 8th Day Software and Consulting, LLC , ... 8th Day Software, based in Tennessee ... Management LLC. 8th Day expands EnvoyHealth,s service offerings for ... product development. "In ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: